CLAIMS

1. Use of a~~A~~ composition ~~for use in the treatment of Parkinsonism,~~ comprising ~~at least two compounds selected from~~ acamprosate~~,~~ and baclofen~~, cinacalcet, mexiletine, sulfisoxazole and torasemide,~~ or a salt, prodrug, derivative of any chemical purity, or sustained release formulation thereof, in the manufacture of a medicament for use in the treatment of parkinsonism in a subject in need thereof.

2. The use of claim 1, wherein said parkinsonism is a condition selected from Parkinson's disease, progressive supranuclear palsy, multiple system atrophy, cortical-basal ganglionic degeneration, diffuse Lewy body disease, Parkinson's dementia, X-linked dystonia-parkinsonism, and secondary parkinsonism.

3. The use of claim 1, wherein said medicament is for treating Parkinson's disease.

~~2.~~4. The ~~composition for~~ use of claims 1 or 3, wherein said medicament comprise~~s~~~~ing~~ at least one of the following drug combinations:

~~- baclofen and acamprosate,~~
~~- baclofen and cinacalcet,~~
~~- mexiletine and cinacalcet,~~
~~- torasemide and baclofen,~~
~~- torasemide and sulfisoxazole,~~
~~- baclofen and cinacalcet and mexiletine,~~
~~- cinacalcet and acamprosate and mexiletine,~~
- baclofen and acamprosate and cinacalcet,
- baclofen and acamprosate and torasemide, or
- baclofen and acamprosate and mexiletine~~, or~~
~~- torasemide and baclofen and cinacalcet.~~

~~3. The composition of claim 1 or 2, for use for treating Parkinson's disease.~~

~~4.~~5. The ~~composition for~~ use of any one of claims ~~3~~1-4, the medicament further comprising ~~levodopa, or a salt, prodrug, derivative of any purity, or sustained release formulation thereof~~ at least one dopamine precursor, at least one dopamine

receptor agonist, and/or at least one inhibitor of dopamine metabolizing enzymes.

6. The use of claim 5, wherein the at least one dopamine precursor is selected from the group consisting of levodopa and melevodopa, or salts, prodrugs, derivative of any purity or sustained release formulation thereof, the at least one dopamine receptor agonist is selected from the group consisting of talipexole, piribedil, rotigotine, bromocriptine, pergolide, cabergoline, lisuride, pramipexole, ropinirole or apomorphine, or salts, prodrugs, derivative of any purity or sustained release formulation thereof, and the at least one inhibitor of dopamine metabolizing enzymes is selected from the group consisting of selegiline and rasagiline, or salts, prodrugs, derivative of any purity or sustained release formulation thereof.

7. The use of claims 5 or 6, the medicament comprising at least one of the following drug combinations:
   - baclofen and acamprosate and levodopa,
   - baclofen and acamprosate and cinacalcet and levodopa,
   - baclofen and acamprosate and torasemide and levodopa, or
   - baclofen and acamprosate and mexiletine and levodopa.

8. The use of claim 7, the medicament further comprising carbidopa or salt, prodrug, derivative of any purity or sustained release formulation thereof.

~~5.~~9. The ~~composition for~~ use of any one of the preceding claims, ~~which~~ the medicament further comprises a pharmaceutically acceptable carrier or excipient.

~~6.~~10. The ~~composition for~~ use of any one of the preceding claims, wherein the compounds are formulated or administered together, separately or sequentially.

~~7.~~11. The ~~composition for~~ use of any one of the preceding claims, wherein said ~~composition~~ medicament is to be administered repeatedly to the subject.

~~8.~~12. The ~~composition for~~ use of any one of the preceding claims, wherein said ~~composition~~ medicament is to be administered orally.

~~9.~~13. The ~~composition for~~ use of any one of claims 1 to ~~7~~11, wherein acamprosate~~, when present,~~ is ~~administered~~provided in said medicament in a dosage of less than 50 mg per day, ~~more preferably~~or less than 10 mg per day.

~~10.~~14. The ~~composition for~~ use of any one of claims 1 to ~~8~~12, wherein baclofen~~, when present,~~ is ~~administered~~ provided in said medicament in a dosage of less than 30 mg per day.

~~11.~~15. The ~~composition~~ use of any one of claims 1 to ~~10~~14, for ~~use in~~ protecting dopaminergic neurons of the nigrostriatal system from degeneration.

~~12.~~16. The ~~composition~~ use of any one of claims 1 to ~~10~~14, for ~~use in~~ the treatment of bradykinesia or akinesia.

~~13. A method of treating Parkinsonism in a mammalian subject in need thereof, the method comprising simultaneously, separately or sequentially administering to said subject an effective amount of a composition of any of the preceding claims.~~

~~14.~~17. The ~~method~~ use of claim ~~13~~1, wherein said subject in need thereof is also treated with deep brain stimulation of the subthalamic nucleus or of the *globus pallidus interna*.

~~15.~~18. The ~~composition or method~~use of any one of the preceding claims, for ~~use in a~~ preventive treatment in a subject in need thereof and at risk of ~~Parkinsonism~~parkinsonism.

19. A composition comprising baclofen, acamprosate and levodopa or any pharmaceutically acceptable salts thereof.